Company: AVCRF
Filing Date: 2025-06-16
Form Type: 20-F
Source: 0001641172-25-015266
Chunk: 41

Company: Avricore Health Inc.
Filing Date: 2025-06-16
Form: 20-F
Item: Item 10
Chunk 41
---
 prominent notice of the dissent right. Dissent provisions are governed by the
BCA and not by the Articles of the Company.

Under
the Articles, a special separate resolution requires a majority of three-quarters of the votes cast.

Shareholders’
Meetings

In
addition to reflecting the present notice and other provisions of the BCA relating to shareholders’ meetings, the Articles provide
that shareholders’ meetings may be held at such place as is determined by the directors. Shareholders meetings are governed by
the Articles of the Company but many important protections and procedures are contained within the BCA and the Securities Act (British
Columbia) and the Securities Act (Alberta) and the respective regulations and rules thereto and the policy statements, notices and blanket
orders of the respective commissions of each of British Columbia and Alberta, together with the national policy statements, and national
instruments applied by the such commissions (collectively, “ Applicable Canadian Securities Law”). The Articles provide that
the Company will hold an annual shareholders’ meeting, will provide at least 21 days’ notice and will provide for certain
procedural matters and rules of order with respect to conduct of the meeting. The BCA and Applicable Canadian Securities Law superimpose
requirements that generally provide that shareholders meetings require not less than a 60 day notice period from initial public notice
and that the Company makes a thorough advanced search of intermediary and brokerage registered shareholdings to facilitate communication
with beneficial shareholders so that meeting proxy and information materials can be sent via the brokerages to unregistered but beneficial
shareholders. The form and content of information circulars and proxies and like matters are governed by Applicable Canadian Securities
Law and includes the specifics relating to disclosure requirements for the proxy materials and various corporate actions, background
information on the nominees for election for director, executive compensation paid in the previous year and full details of any unusual
matters or related party transactions.

  39  

The
Company must hold an annual shareholders meeting open to all shareholders for personal attendance or by proxy at each shareholder’s
determination. The meeting must be held within 15 months of the previous annual shareholders meeting and must present audited statements
which are dated no more than six months prior to such meeting.

Change
in Control

The
Company has not implemented any shareholders’ rights or other “poison pill” protection against possible take-overs.
The Company does not have any agreements which are triggered by a take-over or other change of control. There are